Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 10 of 11
Jan 27, 2026Digital health solutions continue to reshape healthcare delivery, demanding innovative contracting strategies. PHTI’s new playbook outlines how purchasers can effectively apply performance-based contracts to ensure measurable outcomes and accountability in digital health technologies.
TCB Team
Jan 26, 2026The biotech company Revolution Therapeutics currently stands at a crucial junction as multiple pharmaceutical companies potentially eye acquisitions. Merck's recent step back from pursuit places Revolution in a position to reassess its market worth amid growing investor speculation. This development sheds light on the dynamic nature of biopharmaceutical mergers and acquisitions in today's fast-evolving healthcare landscape.
Jonathan Blake
Jan 25, 2026The recent significant fundraising by AnswersNow represents a pivotal development in the domain of autism care. With backing from prominent investors, their strategy to enhance therapy access could have far-reaching effects on service delivery models and patient outcomes for individuals with autism spectrum disorder.
Jonathan Blake
Jan 23, 2026The significant capital infusion will fuel Corxel’s efforts to push CX11 through mid-stage development in the United States and prepare for pivotal Phase III clinical trials, underscoring investor confidence in oral GLP-1 therapies.
Emily Carter
Jan 22, 2026As measles cases rise across the United States, the implications extend beyond public health, impacting hospital finances and the broader healthcare infrastructure. Stakeholders express concern over these intertwined challenges amid warnings from health officials about vaccine complacency and resource constraints.
Dr. Priya Nandakumar
Jan 22, 2026The partnership between BMS and Janux represents a notable step in targeted cancer therapy where the treatment activates only in the vicinity of tumors, aiming to improve efficacy and reduce side effects.
Michael Torres
Jan 22, 2026The world of brain science is experiencing unprecedented growth and interest from investors and innovators alike. Enabled by breakthroughs in biomarkers, brain mapping technologies, and AI applications, the field is moving rapidly. This in-depth analysis explores the current landscape of neuroscience investment and innovation, highlighting key trends and insights from the recent JPM26 conference.
TCB Team
Jan 19, 2026The biopharmaceutical sector is witnessing sustained investor enthusiasm as more companies prepare for public offerings. Insights into current IPO trends reflect the evolving state of the market and investor confidence.
TCB Team
Jan 18, 2026Recent insights emphasize that programs which blend personalized human interaction alongside effective use of technology outperform those relying on technology alone in improving healthcare member engagement, quality outcomes, and retention.
TCB Team
Jan 18, 2026The COVID-19 pandemic left profound emotional and psychological scars on healthcare workers and communities. This opinion piece explores the lingering despair and calls attention to the lack of public accountability and outrage regarding the pandemic's management.
TCB Team
Jan 16, 2026With a substantial fund allocation, the Novo Nordisk Foundation aims to accelerate breakthrough innovations, fostering a sustainable ecosystem for biotechnology and health-related technological advances in both Denmark and the wider European landscape.
TCB Team
Jan 15, 2026The healthcare sector is witnessing unprecedented private equity inflows, marking a record investment milestone in 2025. However, this surge has led to heightened competition among investors for premium assets, influencing market dynamics and raising strategic considerations for future investment and growth.
TCB TeamMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.